Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 3 2

Status

Unknown 2Completed 2

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4Thoracic 1

Conditions

Lymphoma, Follicular 4Asthma 3Pulmonary Disease, Chronic Obstructive 1Bronchial Hyperreactivity 1

Interventions

Rituximab 301Cyclophosphamide 241Peripheral Blood Stem Cell Transplantation 115fludarabine phosphate 111Filgrastim 93Etoposide 85Radiotherapy 81Lenalidomide 81Vincristine 79Prednisone 79Mycophenolic Acid 67Doxorubicin 62Whole-Body Irradiation 59Cyclosporine 59Bendamustine Hydrochloride 59Melphalan 57Tacrolimus 54Busulfan 52obinutuzumab 50fludarabine 50Cytarabine 49Methotrexate 45Antilymphocyte Serum 43Bortezomib 42Methylprednisolone 37Carmustine 37sargramostim 36ibritumomab tiuxetan 33ibrutinib 30Dexamethasone 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Lymphoma, Follicular × Fluticasone-Salmeterol Drug Combination × Clear all
NCT03387241 2019-04-29

Efficacy of FLUTIFORM ® vs Seretide® in Moderate to Severe Persistent Asthma in Subjects Aged ≥12 Years

Mundipharma (China) Pharmaceutical Co. Ltd

Phase 3 Unknown
330 enrolled
Lymphoid

Asthma, Lymphoma, Follicular

NCT03745261 2018-11-19

Effect of Yong Chong Cao Capsule on Outcomes in Patients With Mild to Severe COPD

Henan University of Traditional Chinese Medicine

Phase 3 Unknown
240 enrolled
Lymphoid

Lymphoma, Follicular, Pulmonary Disease, Chronic Obstructive

NCT00455923 2018-02-05

SERETIDE Vs FLIXOTIDE In Mild Persistent Asthma (GINAII)

GlaxoSmithKline

Phase 4 Completed
100 enrolled 8 charts
LymphoidThoracic

Asthma, Lymphoma, Follicular, Bronchial Hyperreactivity

NCT00461500 2017-03-03

SERETIDE 100/50 bd (Twice Daily) Versus FLIXOTIDE 100 bd As Initial Maintenance Therapy In Moderate Asthma In Adults

GlaxoSmithKline

Phase 4 Completed
81 enrolled 18 charts
Lymphoid

Asthma, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡